title: A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.
authors.forename: M W
authors.initials: MW
authors.lastname: Drummond
authors.forename: N
authors.initials: N
authors.lastname: Heaney
authors.forename: J
authors.initials: J
authors.lastname: Kaeda
authors.forename: F E
authors.initials: FE
authors.lastname: Nicolini
authors.forename: R E
authors.initials: RE
authors.lastname: Clark
authors.forename: G
authors.initials: G
authors.lastname: Wilson
authors.forename: P
authors.initials: P
authors.lastname: Shepherd
authors.forename: J
authors.initials: J
authors.lastname: Tighe
authors.forename: L
authors.initials: L
authors.lastname: McLintock
authors.forename: T
authors.initials: T
authors.lastname: Hughes
authors.forename: T L
authors.initials: TL
authors.lastname: Holyoake
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D016044:Fusion Proteins, bcr-abl / Q000032:analysis; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D008875:Middle Aged; D010865:Pilot Projects; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012074:Remission Induction
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl